Power Law company profile

LogicBio Therapeutics

Biotech & Life Sciences · Cambridge, United States · Founded 2015 · IPO 2018 Thoroughbred

Develops gene therapy vectors for previously incurable genetic and infectious diseases including hemophilia, HIV/AIDS, and methylmalonic acidemia

Valuation

$100–500M

Latest valuation · May/2026

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

5 investors on LogicBio Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage

OrbiMed

Series B+ 4 investors entered at this stage

SBI Japan-Israel Innovation Fund

Pontifax Funds

Andera Partners

Arix Bioscience

Global footprint

Where LogicBio Therapeutics has talent and traffic

Workforce by country

🇺🇸 United States · Cambridge HQ

Book a demo for the full country breakdown

Market sentiment

What the market is saying about LogicBio Therapeutics

An AI-synthesized read of the highest-engagement posts about LogicBio Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See LogicBio Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles